药物相互作用：胃肠病学家入门指南。
Drug interactions: a primer for the gastroenterologist.
作者信息
Doligalski Christina Teeter, Tong Logan Angela, Silverman Andrew
机构信息
Dr. Doligalski, Dr. Tong Logan, and Dr. Silverman are all Solid Organ Transplant Pharmacotherapy Specialists at Tampa General Hospital in Tampa, Florida.
出版信息
Gastroenterol Hepatol (N Y). 2012 Jun;8(6):376-83.
Abstract
One of the most clinically significant complications related to the use of pharmacotherapy is the potential for drug-drug or drug-disease interactions. The gastrointestinal system plays a large role in the pharmacokinetic profile of most medications, and many medications utilized in gastroenterology have clinically significant drug interactions. This review will discuss the impact of alterations of intestinal pH, interactions mediated by phase I hepatic metabolism enzymes and P-glycoprotein, the impact of liver disease on drug metabolism, and interactions seen with commonly utilized gastrointestinal medications.
摘要
与药物治疗相关的最具临床意义的并发症之一是药物相互作用或药物与疾病相互作用的可能性。胃肠道系统在大多数药物的药代动力学特征中起着重要作用，胃肠病学中使用的许多药物都存在具有临床意义的药物相互作用。本综述将讨论肠道pH值改变的影响、由I相肝代谢酶和P-糖蛋白介导的相互作用、肝病对药物代谢的影响以及常见胃肠药物之间的相互作用。
相似文献
1
Drug interactions: a primer for the gastroenterologist.药物相互作用：胃肠病学家入门指南。
Gastroenterol Hepatol (N Y). 2012 Jun;8(6):376-83.
2
Drug interactions of macrolides: emphasis on dirithromycin.大环内酯类药物的药物相互作用：重点关注地红霉素。
Ann Pharmacother. 1997 Mar;31(3):349-56. doi: 10.1177/106002809703100314.
3
Macrolide drug interactions: an update.大环内酯类药物相互作用：最新进展
Ann Pharmacother. 2000 Apr;34(4):495-513. doi: 10.1345/aph.19138.
4
Pharmacokinetic drug interactions with antimicrobial agents.药物与抗菌药物的药代动力学相互作用。
Clin Pharmacokinet. 1993 Dec;25(6):450-82. doi: 10.2165/00003088-199325060-00005.
5
Pharmacokinetic drug interactions of macrolides.大环内酯类药物的药代动力学药物相互作用。
Clin Pharmacokinet. 1992 Aug;23(2):106-31. doi: 10.2165/00003088-199223020-00004.
6
Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes.具有临床重要性的药代动力学药物相互作用：细胞色素P450酶的作用
J Clin Pharm Ther. 1998 Dec;23(6):403-16. doi: 10.1046/j.1365-2710.1998.00086.x.
7
Pharmacokinetic drug interaction profiles of proton pump inhibitors.质子泵抑制剂的药代动力学药物相互作用概况。
Drug Saf. 2006;29(9):769-84. doi: 10.2165/00002018-200629090-00002.
8
An update on the role of intestinal cytochrome P450 enzymes in drug disposition.肠道细胞色素P450酶在药物处置中作用的最新进展。
Acta Pharm Sin B. 2016 Sep;6(5):374-383. doi: 10.1016/j.apsb.2016.07.012. Epub 2016 Aug 4.
9
Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery.肝脏和肠道代谢以及P-糖蛋白对环孢素和他克莫司口服给药的作用。
Adv Drug Deliv Rev. 1997 Sep 15;27(2-3):201-214. doi: 10.1016/s0169-409x(97)00043-4.
10
The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.人类细胞色素P450酶在抗癌药物代谢中的作用：对药物相互作用的影响。
Br J Clin Pharmacol. 1995 Dec;40(6):523-30. doi: 10.1111/j.1365-2125.1995.tb05796.x.
引用本文的文献
1
Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database.利用美国食品药品监督管理局不良事件报告系统（FAERS）数据库进行药物重新利用。
Curr Drug Targets. 2024;25(7):454-464. doi: 10.2174/0113894501290296240327081624.
2
Assessment of potential drug-drug interactions among outpatients in a tertiary care hospital: focusing on the role of P-glycoprotein and CYP3A4 (retrospective observational study).三级护理医院门诊患者潜在药物相互作用的评估：聚焦于P-糖蛋白和CYP3A4的作用（回顾性观察研究）
Heliyon. 2022 Oct 28;8(11):e11278. doi: 10.1016/j.heliyon.2022.e11278. eCollection 2022 Nov.
3
Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis.阿夫唑嗪用于良性前列腺增生和下尿路症状的医学治疗：文献系统评价与叙述性综合分析
Ther Adv Urol. 2021 Apr 12;13:1756287221993283. doi: 10.1177/1756287221993283. eCollection 2021 Jan-Dec.
4
Effect of Ticagrelor, a Cytochrome P450 3A4 Inhibitor, on the Pharmacokinetics of Tadalafil in Rats.细胞色素P450 3A4抑制剂替格瑞洛对大鼠他达拉非药代动力学的影响。
Pharmaceutics. 2019 Jul 20;11(7):354. doi: 10.3390/pharmaceutics11070354.
5
Dose Escalation Study to Assess the Pharmacokinetic Parameters of a Nano-amorphous Oral Sirolimus Formulation in Healthy Volunteers.剂量递增研究：评估纳米无定形口服西罗莫司制剂在健康志愿者体内的药代动力学参数
Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):777-785. doi: 10.1007/s13318-019-00562-y.
6
The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide.舒尼替尼对静脉注射对乙酰氨基酚及其主要代谢产物——对乙酰氨基酚葡萄糖醛酸苷血浆暴露量的影响。
Eur J Drug Metab Pharmacokinet. 2015 Jun;40(2):163-70. doi: 10.1007/s13318-014-0191-z. Epub 2014 Mar 28.
本文引用的文献
1
Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes.减重手术后口服药物生物利用度的变化趋势：不同药物类别的暴露影响程度不一。
Br J Clin Pharmacol. 2012 Nov;74(5):774-87. doi: 10.1111/j.1365-2125.2012.04284.x.
2
Role of transporters in drug interactions.转运体在药物相互作用中的作用。
Arch Pharm Res. 2011 Nov;34(11):1865-77. doi: 10.1007/s12272-011-1107-y. Epub 2011 Dec 3.
3
Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail.替拉那韦、波普瑞韦、细胞色素P450和免疫抑制剂——一种潜在的致命组合。
Hepatology. 2011 Jul;54(1):3-5. doi: 10.1002/hep.24470.
4
Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus.替拉瑞韦对环孢素和他克莫司药代动力学的影响。
Hepatology. 2011 Jul;54(1):20-7. doi: 10.1002/hep.24443.
5
Clopidogrel with or without omeprazole in coronary artery disease.氯吡格雷联合或不联合奥美拉唑用于冠心病。
N Engl J Med. 2010 Nov 11;363(20):1909-17. doi: 10.1056/NEJMoa1007964. Epub 2010 Oct 6.
6
Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics.大环内酯类抗生素抑制地高辛及其代谢物的 P-糖蛋白介导外排。
J Pharmacol Sci. 2010;113(4):315-24. doi: 10.1254/jphs.10109fp.
7
A systematic review of drug absorption following bariatric surgery and its theoretical implications.减重手术后药物吸收的系统评价及其理论意义。
Obes Rev. 2010 Jan;11(1):41-50. doi: 10.1111/j.1467-789X.2009.00614.x. Epub 2009 Jun 2.
8
Cystic fibrosis.囊性纤维化
Lancet. 2009 May 30;373(9678):1891-904. doi: 10.1016/S0140-6736(09)60327-5. Epub 2009 May 4.
9
Reduced duodenal cytochrome P450 3A protein expression and catalytic activity in patients with cirrhosis.肝硬化患者十二指肠细胞色素P450 3A蛋白表达及催化活性降低。
Clin Pharmacol Ther. 2009 Apr;85(4):387-93. doi: 10.1038/clpt.2008.292. Epub 2009 Feb 11.
10
Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.肝功能不全患者的药代动力学及剂量调整
Eur J Clin Pharmacol. 2008 Dec;64(12):1147-61. doi: 10.1007/s00228-008-0553-z. Epub 2008 Sep 2.
Zotero 插件